Appeal Partially Allowed with Remand for Reconsideration

The appeal was partly allowed, with certain issues remanded back to the Dispute Resolution Panel (DRP) and Transfer Pricing Officer (TPO) for reconsideration. The Tribunal directed the exclusion of Suven Life Sciences from the list of comparables, emphasizing the importance of detailed consideration and appropriate adjustments in determining the Arm's Length Price (ALP) and related computations.

---

---

Issues Involved:
1. Transfer Pricing Adjustments
2. Grant of Working Capital Adjustment
3. Filters
4. Comparables
5. Incorrect Computation of Margin of Appellant
6. Use of Multiple Year Data
7. Risk Profile for Captive Service Provider
8. Computation of Interest Liability under Sections 234B and 234C

Detailed Analysis:

1. Transfer Pricing Adjustments:
The assessee challenged the assessment order passed under section 143(3) read with section 144C and section 92CA(3) of the Income Tax Act, 1961. The primary contention was against the determination of the Arm's Length Price (ALP) and the resultant transfer pricing adjustment of Rs. 1,02,32,356. The assessee claimed that the economic analysis undertaken was in accordance with the Act and the Income-tax Rules, 1962, which was rejected by the DRP/AO.

2. Grant of Working Capital Adjustment:
The assessee argued for a working capital adjustment based on Rule 10B(1)(e)(iii) of the Rules, citing differences in debtors and creditors materially affecting net profit margins. The TPO denied the adjustment due to lack of exact details and non-uniformity in receivables and payables among comparable companies. The DRP confirmed the TPO's decision. The Tribunal found that the DRP did not consider the assessee's detailed submissions and remanded the issue back to the DRP for reconsideration and a speaking order.

3. Filters:
The assessee contested the application of diminishing revenue/persistent losses filter by the TPO. The Tribunal upheld the AO's decision, stating that only functionally comparable companies should be adopted for ALP determination and companies with persistent losses or diminishing revenue cannot be considered comparables.

4. Comparables:
- Suven Life Sciences Ltd: The assessee argued against its inclusion as a comparable due to functional dissimilarity. The Tribunal agreed, noting that Suven Life Sciences was involved in complex R&D and drug discovery activities, unlike the assessee's simple drug testing services. The Tribunal directed the AO to exclude Suven Life Sciences from the list of comparables.
- Incorrect Margins: The assessee claimed incorrect margins were adopted for TCG Lifesciences Ltd, Manipal Acunova Ltd, and Choksi Laboratories Ltd. The Tribunal remanded the matter to the TPO to analyze the impact of provisions for bad and doubtful debts on margins and make suitable adjustments.

5. Incorrect Computation of Margin of Appellant:
The assessee contended that the forex loss should not be considered as an operating loss. The Tribunal noted that while the issue was generally decided against the assessee, the loss arising subsequent to the date of invoice should not be considered as operating loss. The issue was remanded to the AO for verification.

6. Use of Multiple Year Data:
The Tribunal did not specifically address this issue as it was not pressed by the assessee during the hearing.

7. Risk Profile for Captive Service Provider:
The Tribunal did not specifically address this issue as it was not pressed by the assessee during the hearing.

8. Computation of Interest Liability under Sections 234B and 234C:
The Tribunal did not specifically address this issue as it was not pressed by the assessee during the hearing.

Conclusion:
The appeal was partly allowed. The Tribunal remanded certain issues back to the DRP and TPO for reconsideration and directed the exclusion of Suven Life Sciences from the list of comparables. The order emphasized the need for detailed consideration and appropriate adjustments in determining the ALP and related computations.

---